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ChildBackground: The availability of a COVID-19 vaccine has been heralded as key to controlling the COVID-19
pandemic. COVID-19 vaccination programme success will rely on public willingness to be vaccinated.
Methods: We used a multi-methods approach - involving an online cross-sectional survey and semi-
structured interviews - to investigate parents’ and guardians’ views on the acceptability of a future
COVID-19 vaccine. 1252 parents and guardians (aged 16 + years) who reported living in England with
a child aged 18 months or under completed the survey. Nineteen survey participants were interviewed.
Findings: Most survey participants reported they would likely accept a COVID-19 vaccine for themselves
(Definitely 55.8%; Unsure but leaning towards yes 34.3%) and their child/children (Definitely 48.2%;
Unsure but leaning towards yes 40.9%). Less than 4% of survey participants reported that they would def-
initely not accept a COVID-19 vaccine. Survey participants were more likely to accept a COVID-19 vaccine
for themselves than their child/children. Participants that self-reported as Black, Asian, Chinese, Mixed or
Other ethnicity were almost 3 times more likely to reject a COVID-19 vaccine for themselves and their
children than White British, White Irish and White Other participants. Survey participants from lower-
income households were also more likely to reject a COVID-19 vaccine. In open-text survey responses
and interviews, self-protection from COVID-19 was reported as the main reason for vaccine acceptance.
Common concerns identified in open-text responses and interviews were around COVID-19 vaccine
safety and effectiveness, mostly prompted by the newness and rapid development of the vaccine.
Conclusion: Information on how COVID-19 vaccines are developed and tested, including their safety and
efficacy, must be communicated clearly to the public. To prevent inequalities in uptake, it is crucial to
understand and address factors that may affect COVID-19 vaccine acceptability in ethnic minority and
lower-income groups who are disproportionately affected by COVID-19.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Over 33 million confirmed cases of coronavirus (COVID-19),
including more than 1 million deaths, have been reported globally
since the start of the COVID-19 pandemic to 29th September 2020
[1]. COVID-19 has spread to almost every country in the world,
resulting in excess mortality and serious social and economic
disruptions.
According to COVID-19 mortality figures, the UK is one of the
worst affected countries in the world, with over 440,000 cases
and 42,000 deaths reported as of 29th September 2020 [1,2].In efforts to slow the spread of COVID-19 in the UK, stringent
restrictions on movement were enforced on 23rd March 2020, with
the general public directed to only leave their homes to: shop for
basic essentials, take one form of exercise per day, access medical
care or help a vulnerable person, and to travel to and from work if
absolutely necessary (where unable to work from home) [3]. Peo-
ple most at-risk from COVID-19 were asked to protect themselves
by shielding from 23rd March 2020: staying at home at all times,
for at least 12 weeks. In addition, schools were closed to all but vul-
nerable children and children of key workers [3].
Although restrictions to slow COVID-19 spread have eased in
many countries, including the UK, day-to-day life globally remains
distinctly marked by the COVID-19 pandemic, and measures to
prevent COVID-19 spread [4]. A COVID-19 vaccine has been her-
alded as key to ending the pandemic and clinical trials to develop
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ated rate [5,6]. To date, over 160 COVID-19 vaccine candidates
are under development, with 26 in human trials [6]. In the UK, a
Vaccine taskforce has been created to ‘drive forward, expedite
and co-ordinate efforts to research and then produce a coronavirus
vaccine and make sure one is made available to the public as
quickly as possible’ [5]. On 20th July 2020, the UK government
secured early access to 90 million doses of promising COVID-19
vaccines, ‘giving the UK the most likely chance of getting access
to a safe and effective vaccine at the quickest speed’ [7].
In planning for the near-future availability of a COVID-19 vac-
cine, as well as focusing on how to deliver COVID-19 vaccine pro-
grammes and ensure equitable vaccine allocation globally [8], it is
crucial to explore the acceptability of a COVID-19 vaccine to the
public. The success of any COVID-19 vaccination programme will
depend on public willingness to receive the vaccination.
In the UK, the Joint Committee on Vaccination and Immunisa-
tion (JCVI), have provisionally advised that if and when a COVID-
19 vaccine becomes available the priority should be to vaccinate
those at highest risk of COVID-19 exposure, transmission and sev-
ere COVID-19 disease [9]. The JCVI has communicated a prelimi-
nary list of priority groups to receive the vaccine that targets
those most at risk of disease although it recognises that depending
on future vaccine characteristics, it may be that vaccinating young
and healthy members of the population will help to prevent
COVID-19 transmission to high-risk groups and also reduce soci-
etal and economic disruption.
In recognition that a COVID-19 vaccine could be made eligible
to the majority of the population, we conducted a multi-methods
study to investigate the views of parents and guardians in England
on the acceptability of a future COVID-19 vaccine, for themselves
and their children.
2. Methods
We used a multi-methods approach – combining qualitative
and quantitative methods – with the aim of gaining a more com-
plete insight into the acceptability of a future COVID-19 vaccine.
The study utilised a cross-sectional questionnaire survey and
semi-structured interviews, to quantify the prevalence of different
views on COVID-19 vaccine acceptability, and to explore reasons
behind these views. The questions asked regarding COVID-19 vac-
cine acceptance were part of a larger study exploring parents’ and
guardians’ views and perceptions towards childhood vaccinations
and use of NHS general practice services for childhood vaccination
during the COVID-19 pandemic
3. Cross-sectional survey
3.1. Recruitment
Survey recruitment took place between 19th April and 11th
May 2020. Eligible participants were required to be (1) a parent
or guardian of a child (or children) aged 18 months or under, (2)
a resident of England, and (3) aged 16 + years. Participants were
provided with full study details before starting to complete the
survey (see supplemental file 1), explaining all aspects of participa-
tion including their right to withdraw from the research and issues
surrounding confidentiality and data protection. Before completing
the survey, participants were required to indicate their consent
through the use of a forced response question. It was made clear
that only the recorded data from participants that completed the
full survey would be used in later analysis.
We utilised an online social media strategy to recruit survey
participants. This strategy involved the creation of a Facebook page
dedicated to the study with a single post advertising the study,7790outlining the eligibility criteria for participation, and including
the hyperlink to the survey. An email was then sent to organisers
of 284 baby and toddler play groups in England. This contact email
included a study summary and a request to share the advertising
post through the groups various means of communication (e.g.
Facebook, WhatsApp, Twitter or an email list). In addition to this,
Facebook’s paid promotion feature was used to target the survey
at eligible potential participants.
3.2. Survey design and pre-testing
The survey was developed by the study researchers in consulta-
tion with immunisation representatives from Public Health Eng-
land. In the refinement of the survey questions and layout, we
gained feedback from parents with young children on the compre-
hensibility, usability and time taken to complete the survey from
the perspective of the target audience.
3.3. Measures
Thesurvey includeddemographicquestions concerningage, gen-
der, household income, employment, marital status of participants,
and number and age of children. Two questions were designed to
capture acceptance of a new COVID-19 vaccination. The text of the
questions read ‘‘If a new coronavirus (COVID-19) vaccine became
availablewouldyouaccept thevaccine for yourself?” and ‘‘If anewcoro-
navirus (COVID-19) vaccine became available would you accept the
vaccine for your child/children?”. A 4-point Likert scale was used to
encourage participants to take a stance on the vaccine (rather than
selecting a ‘do not know’ answer). The Likert scale options were
‘‘Yes, definitely”, ‘‘Unsure but leaning towards yes”, ‘‘Unsure but leaning
towards no” and ‘‘No, definitely not”. Open-text boxes were included
for participants to explain their responses to the two questions on
vaccine acceptability for themselves and for their children. Partici-
pants could give more than one reason in the open-text boxes.
3.4. Analysis
A paired samples t-test was used to compare acceptance of a
COVID-19 vaccine for self and for the participant’s child. Two sub-
sequent logistic regressions were then conducted to determine the
demographic factors associated with rejection of the COVID-19
vaccine for both self-vaccination and that of the participant’s child.
Alpha was set to 0.05 for all tests. Age, household income, ethnic-
ity, location, and employment were included as predictive vari-
ables in the logistic regression models. In the logistic regression
model for child vaccination, number of children was also included
as a predictive variable.
To perform the logistic regressions ethnicity was dichotomised
into ‘White’ (i.e. White British, White Irish and White Other partic-
ipants) and ‘Black, Asian or minority ethnic (BAME)’ (i.e. Black, Asian,
Chinese, Mixed or Other ethnicity). Household income brackets
were reduced to a ‘‘low income” (<£35,000), ‘‘medium income”
(£35,000 - £84,999) and ‘‘high income” (>£85,000), and the vaccine
acceptance variables were dichotomised into ‘‘likely to accept”
(those that answered Yes, definitely or Unsure but leaning towards
yes) and ‘‘likely to reject” (those that answered No, definitely not
or Unsure but leaning towards no).
Open text responses were analysed thematically in Microsoft
Excel by PP. Coding schemes were produced based on the content
of the open-text comments and discussed by PP and SB.
3.5. Semi-structured interviews
On completing the survey, participants were asked to provide
their contact details if interested in taking part in a follow-up
Table 1
Characteristics of survey participants.
Characteristic Frequency
(%)
Location
South East 286 (22.8)
Greater London 164 (13.1)
North West 90 (7.2)
East of England 231 (18.5)
West Midlands 98 (7.8)
South West 139 (11.1)
Yorkshire and the Humber 116 (9.3)
East Midlands 70 (5.6)
North East 53 (4.2)
Prefer not to answer 5 (0.4)
Ethnicity
White:- British 1082 (86.4)
White:- Irish 20 (1.6)
White:- Other white background 76 (6.1)
Black or Black British:- African 3 (0.2)
Black or Black British:- Caribbean 1 (0.1)
Mixed:- White and Black Caribbean 7 (0.6)
Mixed:- White and Black African 1 (0.1)
Mixed:- White and Asian 9 (0.7)
Mixed:- Other mixed background 7 (0.6)
Asian or Asian British:- Indian 15 (1.2)
Asian or Asian British:- Pakistani 10 (0.8)
Asian or Asian British:- Bangladeshi 3 (0.2)
Asian or Asian British:- Other Asian
background
3 (0.2)
Chinese 2 (0.2)
Other ethnic group not represented by these
options
7 (0.6)
Do not wish to say 6 (0.5)
Employment status
Working full-time (over 30 h per week) or on
parental leave from full time employment
679 (54.2)
Working part-time (less than 30 h per week) 404 (32.3)
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were purposively selected based on a range of characteristics,
including ethnicity, household income, and geographical location.
We purposefully aimed to interview survey participants who did
not complete open text responses and presented characteristics
of interest such as underrepresented populations in the survey
(e.g. participants from ethnic minority groups or reporting a lower
household income) and/or indicated they would likely refuse a
COVID-19 vaccine, for their child or themselves. We did not solely
interview participants who were likely to refuse a COVID-19 vac-
cine as we were keen to explore the nuances of reasons partici-
pants had for accepting or refusing a COVID-19 vaccine.
Participants were emailed an information sheet, fully detailing
the study objectives and explaining all aspects of participation,
including the right to withdraw from the research. Written
informed consent was obtained from each participant. Interviews
lasted approximately 30 min and were conducted over the phone.
Topic guides, shaped around the content of the questionnaire, were
used to assist the interviews. The interviews included two ques-
tions related to a COVID-19 vaccination, the first focused on par-
ents’ and guardians’ views on receiving a new COVID-19 vaccine
for themselves, should one become publicly available, and the sec-
ond on their views on their child of accepting a new COVID-19 vac-
cine for their child. Interview participants received a £10 gift
voucher as a thank you for their time and contribution. The inter-
views took place between 27th April and 27th May 2020.
Interviews were transcribed verbatim and analysed themati-
cally in NVivo12 by using the stages outlined by Braun and Clarke
[10]: data familiarisation, coding and theme identification and
refinement. The transcribed interviews were read and coded by
SB. To enhance the rigour of the analysis, coding approaches and
subsequent theme generation and refinement was discussed
between SB and the other researchers.or on parental leave from part time
employment
Homemaker 114 (9.1)
Student 12 (0.9)
Unemployed 13 (1.0)
Other 23 (1.8)
Prefer not to answer 7 (0.6)
Household income (GBP)
Under £34,999 255 (20.4)
£35,000–£84,999 638 (51.0)
£85,000 and over 267 (21.3)
Prefer not to answer 92 (7.3)
Number of children
1 558 (44.6)
2 504 (40.3)
3 148 (11.8)
4 or more 42 (3.4)
Age of youngest child
< 2 months 223 (18.0)
3–5 months 330 (26.6)4. Findings
1252 parents and guardians completed the survey (see partici-
pant characteristics in Table 1). Most survey participants were
female (95.0%; n = 1190), raising a child/children with a partner
(97.0%; n = 1214), and identified as beingWhite British, White Irish
or White Other (94.1%; n = 1178). The age range of participants was
18–48 years (Mean = 32.95, SD = 4.565). Median household income
was reported as £55,000-£64,999. Of the survey participants, 1049
(83.8%) left open-text responses to the open text survey questions.
43.3% of survey participants (n = 530) provided their details to
be contacted for a follow-on interview. In total, 61 parents were
contacted to participate. Of these 19 took part in interviews (18
women and one man), 39 did not respond to recruitment emails,
two responded initially but did not follow through with an inter-
view. The characteristics of interviewees are outlined in Table 2.6–8 months 179 (14.4)
9–11 months 154 (12.3)
12–14 months 218 (17.6)
>15 months 138 (11.1)4.1. Quantitative findings - acceptability of a future COVID-19
vaccination
A high proportion of survey participants reported that they
would definitely accept or were unsure but leaning towards
accepting a COVID-19 vaccine for themselves (Yes, definitely
55.8%, n = 699; Unsure but leaning towards yes 34.3%, n = 429)
and their child/children (Yes, definitely 48.2%, n = 604; Unsure but
leaning towards yes 40.9%, n = 512) (Table 3). <1 in 10 participants
reported that they were unsure but leaning towards rejecting or
would definitely reject a COVID-19 vaccine for themselves (Unsure
but leaning towards no 6.2%, n = 78; No, definitely not 3.7%, n = 46)
and their child/children (Unsure but leaning towards no 7.4%,
n = 93; No, definitely not 3.4%, n = 43).7791Participants were more likely to say that they would definitely
accept or were leaning towards accepting a COVID-19 vaccine for
themselves (mean = 2.42, SD = 0.768) than for their child/children
(mean = 2.34, SD = 0.761), t (1251) = 7.636p < .001.
4.2. Survey open-text and interview findings: Main reasons for
accepting the vaccine
Of the survey participants that stated they would definitely
accept or were unsure but leaning towards accepting a COVID-19
Table 2
Characteristics of interview participants.
No. Age Ethnicity Region Household
Income
No. of
children
Age of
youngest
child at time
of interview
Response to: If a new coronavirus
(COVID-19) vaccine became available
would you accept the vaccine for your
child/children?
Response to: If a new coronavirus
(COVID-19) vaccine became
available would you accept the
vaccine for yourself?
#1 25 Mixed:-
White and
Asian
South
East
Under
£34,999
1 13 wks Unsure but leaning towards yes Unsure but leaning towards yes
#2 33 White: -
Other
white
background
South
West
Prefer not
to answer
4 ~ 13 mos Yes definitely Yes definitely
#3 28 White
British
East
Midlands
£35,000–
£84,999
2 ~17 wks Unsure but leaning towards yes Yes definitely
#4 30 White
British
South
West
£85,000
and over
1 8.5 mos Yes definitely Yes definitely
#5 31 White
British
Yorkshire
and
Humber
£35,000–
£84,999
2 14 wks Unsure but leaning towards yes Unsure but leaning towards yes
#6 39 White
British
South
West
£35,000–
£84,999
3 12 wks Unsure but leaning towards yes Unsure but leaning towards yes
#7 36 White
British
Greater
London
£85,000
and over
2 3 mos Unsure but leaning towards yes Unsure but leaning towards yes
#8 36 White: -
Other
white
background
Greater
London
£85,000
and over
2 15 wks Unsure but leaning towards no Unsure but leaning towards yes
#9 33 White
British
South
East
Under
£34,999
2 14 mos Yes definitely Yes definitely
#10 34 Mixed:-
White and
Black
Caribbean
West
Midlands
£85,000
and over
1 9 wks Unsure but leaning towards yes Unsure but leaning towards yes
#11 34 White
British
South
West
£35,000–
£84,999
1 13.5 mos Yes definitely Yes definitely
#12 39 White
British
East
Midlands
£35,000–
£84,999
2 13.5 wks Unsure but leaning towards yes Unsure but leaning towards yes
#13 33 Asian or
Asian
British: -
Pakistani
Greater
London
£35,000–
£84,999
1 6 wks Yes definitely Yes definitely
#14 38 White
British
South
East
Under
£34,999
2 5 mos Unsure but leaning towards no Unsure but leaning towards no
#15 32 White: -
Other
white
background
East of
England
Under
£34,999
1 12 mos Yes definitely Yes definitely
#16 42 White
British
East of
England
£35,000–
£84,999
1 13.5 mos Yes definitely Yes definitely
#17 32 White
British
South
West
Under
£34,999
1 12 mos 3 wks Unsure but leaning towards no Unsure but leaning towards yes
#18 34 Chinese Greater
London
£85,000
and over
2 11 wks Unsure but leaning towards yes Unsure but leaning towards yes
#19 25 Mixed:-
White and
Black
Caribbean
West
Midlands
£35,000–
£84,999
2 12 wks Unsure but leaning towards yes Unsure but leaning towards yes
S. Bell, R. Clarke, S. Mounier-Jack et al. Vaccine 38 (2020) 7789–7798vaccine for themselves (n = 1128), 897 gave an open-text reason
(79.5%). Of the 1116 participants that stated they would definitely
accept or were leaning towards accepting a COVID-19 vaccine for
their child, 925 gave an open-text reason (82.9%).
Most interviewees said that they would definitely accept or
were unsure but leaning towards accepting a COVID-19 vaccine
for themselves (n = 18) and their children (n = 16) in their survey
responses (see Table 2). Interestingly, one interviewee (#19) that
was leaning towards accepting the vaccine at the time of
completing the survey discussed that she was leaning towards
refusing the vaccination (for herself and her child) at the time of
interview.
The following reasons were given for COVID-19 vaccine accep-
tance for self and for child/children, in order of how often they
were mentioned by survey participants and importance to7792interviewees (see Fig. 1 for the main reasons for accepting the
vaccine).
4.2.1. To protect self and others
Of survey participants expressing positive intentions to vacci-
nate and leaving an open-text response, the most prevalent reason
was to provide protection from COVID-19 to the person being vac-
cinated (for self: 42.4%, n = 380; for child: 42.5%, n = 393), followed
by protecting other people (for self: 23.7%, n = 213; for child: 19.5%,
n = 180), including family members (for self: 12.2%, n = 109; for
child: 5.3%, n = 49). Participants also reported that they would vac-
cinate to protect someone known to them in a risk group for
COVID-19 (for self: 8.2%, n = 74; for child: 3.1%, n = 29). 5.0%
(n = 45) of survey participants specifically mentioned that they
wanted to receive the vaccine to stay healthy to look after their
Table 3
Self-reported indication of COVID-19 vaccine acceptance among parents and
guardians with a child aged 18 months or under.
Question Frequency (%)
If a new coronavirus (COVID-19) vaccine became available would you accept
the vaccine for you child/children?
Yes, definitely 604 (48.2)
Unsure but leaning towards yes 512 (40.9)
Unsure but leaning towards no 93 (7.4)
No, definitely not 43 (3.4)
Total 1252 (100)
If a new coronavirus (COVID-19) vaccine became available would you accept
the vaccine for yourself?
Yes, definitely 699 (55.8)
Unsure but leaning towards yes 429 (34.3)
Unsure but leaning towards no 78 (6.2)
No, definitely not 46 (3.7)
Total 1252 (100)
S. Bell, R. Clarke, S. Mounier-Jack et al. Vaccine 38 (2020) 7789–7798child/children. Interviewees also corroborated these findings. They
also highlighted that vaccinating would make them feel safer in
visiting older family members.
‘. . .. for us, I definitely want that. I’d want us protected as a family.
You know, my parents, his [partner’s] parents are ageing, so we’d
be going to see them, and I don’t want to put them at risk. So, cer-
tainly, I think it’s really important.’ (Interview #13)
Several survey participants cited that they would vaccinate as
they were key workers (e.g. involved in health and social care, edu-
cation and childcare, or the food sector) and in frequent contact
with other people (6.7%; n = 60). Health and social care workers
particularly noted a need to vaccinate to protect themselves and
‘at risk’ patients and clients.
4.2.2. Vaccination as a route to ‘returning to normal life’
For several interviewees, the availability of a vaccine was
viewed as the only way of ending social-distancing measures and
returning to normal life. Interviewees talked about lockdown as
being financially unsustainable, and detrimental to physical and
mental wellbeing and children’s educational and social develop-
ment. Interviewees that were shielding during the pandemic wereFig. 1. Main reasons for a
7793particularly keen to accept a future vaccine, with one parent who
had looked into entering a COVID-19 vaccine trial saying they
‘would be first at the door’.
Survey participants also indicated that they would be vacci-
nated (3.7%; n = 33) and get their children vaccinated (2.6%;
n = 24) as a means of stopping the need for social distancing and
returning to normality.
‘. . .society can’t go back to normal until most of us are immune. A
vaccine is the quickest way to achieve that’ (Survey participant
#346).
‘I believe in the importance of all recommended vaccinations for
my child anyway and worry about her [participant’s daughter]
contracting COVID-19. I also worry about her [participant’s daugh-
ter] losing out on normal experiences such as seeing relatives and
friends, going to classes and preschool etc. if we cannot manage
the pandemic.’ (Survey participant #857)4.2.3. Trust and belief in the importance of vaccination
Survey participants indicated that they would receive the vac-
cine for themselves (5.1%; n = 46) or their child/children (7.0%;
n = 65) if it was recommended by the government or healthcare
workers. Survey participants cited their belief in the importance
of vaccination as a reason to receive the vaccination themselves
(3.9%; n = 35) or to vaccinate their children (5.4%; n = 50).
‘I trust that if vaccines are approved for general use and recom-
mended by NHS, they are safe.’ (Survey participant #83)
A proportion of survey participants specifically reported trust in
vaccinations, science or healthcare workers as a prompt to vacci-
nate their child/children (4.1%; n = 38) and themselves (2.7%;
n = 24).
4.2.4. Less risk in vaccinating adults
Interviewees and survey participants discussed a greater will-
ingness to ‘risk’ receiving the vaccination for themselves than for
their children due to safety concerns. Survey participants also
reported the perception that it was less risky to vaccinate adults
than children (3.2%; n = 29) as the vaccine trials were conducted
in adults.ccepting the vaccine.
S. Bell, R. Clarke, S. Mounier-Jack et al. Vaccine 38 (2020) 7789–7798‘I feel safer having the vaccine as an adult as trial would be based
on adults’ (Survey participant #370)4.3. Survey open-text and interview findings: main reasons for not
accepting the vaccine
Of the participants that stated they would definitely reject or
were unsure but leaning towards rejecting a COVID-19 vaccine
for themselves (n = 124), 100 left an open-text reason (80.6%). Of
the 136 participants that stated they would definitely reject or
were leaning towards rejecting a COVID-19 vaccine for their child,
124 (91.2%) gave an open-text response. Three interviewees
reported that they were unsure but leaning towards rejecting a
COVID-19 vaccine for their child/children. One interviewee (#14)
was leaning towards rejecting a COVID-19 vaccine both for them-
selves and their child (see Table 2).
The following reasons were given for COVID-19 vaccine rejec-
tion by survey participants and interviewees (see Fig. 2 for the
main reasons for not accepting the vaccine).
4.3.1. Vaccine safety and effectiveness concerns
The most common concerns expressed by survey participants
about a COVID-19 vaccine were around vaccine safety (for self:
49.0%, n = 49; for child: 62.1%, n = 77) and effectiveness (for self:
11.0%, n = 11; for child: 8.1%, n = 10), which were largely
prompted by the newness and rapid development of the vaccine
(for self: 50.0%; n = 50; for child: 67.7%; n = 84), and the newness
of COVID-19 (for self: 3.0%, n = 3; for child: 4.0%, n = 5). Partici-
pants were worried that the development process might be too
rapid, not allowing enough time for adequate testing to confirm
the vaccine’s short and long-term safety, and also vaccine
effectiveness.
These concerns were echoed by interviewees who had reserva-
tions around how a vaccine developed in a fraction of the usual
timeline for vaccine development could be confirmed as safe.Fig. 2. Main reasons for not
7794‘I’m very pro-vaccines in general, but my main concern was as long
as it hasn’t been rushed through. As long as we know it’ safe and all
the proper tests have been done, and, you know, when you sort of
heard things in the news like well, it’s been 18 years and they
haven’t developed a SARS vaccines, or whatever it was that was
sort of banded around yesterday, it sort of makes you go, why is
that? So, I think that if a vaccine was to come out like this one could
do in a hurry it need to have associated information to how this has
been able to happen so quickly.’ (Interviewee #19)
Some survey participants and interviewees wanted to ‘wait-
and-see’ if the vaccination was safe before being vaccinated them-
selves, or getting their children vaccinated. One interviewee dis-
cussed preferring for her family to remain in lockdown for longer
(i.e. living for a longer duration with the restrictions implemented
on 23rd March 2020), to allow more time for vaccine development
and safety testing. This interviewee acknowledged this situation as
not a financially viable option for those unable to work from home.
4.3.2. Children less at risk of COVID-19
Some survey participants expressed a lack of benefit to vacci-
nating their children, citing that children are hardly affected, are
at lower risk of severe COVID-19 infection than adults (19.4%,
n = 24), and less likely to catch or transmit COVID-19 (3.2%,
n = 4). Participants and interviewees discussed the decision to vac-
cinate their children in terms of balancing potential advantages
and disadvantages. The perception that children are less at risk
of COVID-19 was combined with safety concerns as a reason not
to vaccinate.
‘Any vaccine for covid-19 will have been produced in a huge hurry,
possibly bypassing some of the normal processes and procedures
that ensure safety. As small children have a very low risk of being
seriously ill from the virus, I’m not sure I would risk it. I would
encourage my mum, who is 70 with underlying health conditions,
to take it though as the risk /reward is different.’ (Survey partici-
pant #1095)accepting the vaccine.
S. Bell, R. Clarke, S. Mounier-Jack et al. Vaccine 38 (2020) 7789–7798Several survey participants indicated that they would be more
likely to get their child/children vaccinated if this was beneficial
in reducing COVID-19 spread to older people and clinical risk
groups.
4.3.3. Low perception of risk
Some survey participants indicated not needing the vaccine as
they (16.0%, n = 16) and their child/children (3.2%, n = 4) were
‘fit and healthy’ and not in an at-risk group. 2% of participants
(n = 2) indicated that it was better to prioritise ‘at-risk’ groups
for vaccination.
4.3.4. Already had COVID-19
A small number of survey participants indicated that they
would not accept a COVID-19 vaccine for themselves or their
child/children as they (6.0%, n = 6) or their child (3.2%, n = 4) had
already had COVID-19.
4.3.5. Need for transparency to make an informed vaccine decision
To be able to make an informed choice about vaccination, par-
ents expressed a need for transparent information on vaccine
development, vaccine efficacy and vaccine safety. A lack of vaccine
information at present was given as a reason not to accept the vac-
cine for a minority of survey participants for their children (4.8%,
n = 6) and for themselves (1.0%, n = 1). One interviewee also dis-
cussed that the information should come from trusted sources
such as healthcare professionals, the NHS and Public Health
England.
‘. . .if the NHS is telling you something you’re more likely to believe
it, whereas if it’s a politician, you know, you’ve got much more
incentive to think, ‘‘Well, are they telling the truth?” (Interviewee
#17)4.3.6. Lack of trust
A small number of survey participants stated a lack of trust in
vaccinations, science or the medical profession as a reason to not
accept a vaccine (for self: 4.0%, n = 4; for child: 1.6%, n = 2).
4.4. Quantitative findings – Factors associated with COVID-19 vaccine
rejection for self
A forward stepwise logistic regression analysis was performed
with a dichotomised version of the self-vaccination against
COVID-19 variable as the discrete variable. Age, household income,
ethnicity, location and employmentwere included as predictive vari-
ables. The final model included three predictor variables (household
income, employment and ethnicity) and significantly predicted
‘Likely to reject’ (omnibus chi-square = 50.225, df = 7, p < .001).
Age and location did not significantly predict ‘Likely to reject’, as
such they are excluded from the model. The Hosmer-Lemeshow
test demonstrates that the model adequately fits the data chi-
square = 4.239, df = 7, p = .752. Table 4 gives coefficients and the
Wald statistic, odds ratio and associated degrees of freedom for
each of the predictor variables.
Participants in the lower household income bracket (<£35,000)
were almost twice (OR: 2.08, 95%CI: 1.31–3.3) as likely to reject a
COVID-19 vaccine than participants with a medium household
income (£35,000-£84,999). Those in the highest income bracket
(>£85,000) were almost three times (OR: 0.35, 95%CI: 0.17–0.73)
as likely to accept the vaccine as middle-income bracket partici-
pants (£35,000-£84,999).
Participants that self-reported as Black, Asian, Chinese, Mixed or
Other ethnicity were 2.7 times (95%CI: 1.27–5.87) more likely to
reject a COVID-19 vaccine than White British, White Irish and7795White Other participants. There was also some indication that
those that identify their employment as homemaker were more
likely to reject the vaccination than those in full time employment
or on parental leave from full time employment.
4.5. Quantitative findings – Factors associated with COVID-19 vaccine
rejection for child
A forward stepwise logistic regression analysis was performed
with a dichotomised version of the child vaccination against
COVID-19 variable as the discrete variable. Age, household income,
ethnicity, location, employment and number of children were
included as predictive variables. The final model included three
predictor variables (income, ethnicity and number of children) and
significantly predicted ‘Likely to reject’ (omnibus chi-
square = 37.896, df = 6, p < .001). Age, location and employment
did not significantly predict ‘Likely to reject’, as such they were
excluded from the model. The Hosmer-Lemeshow test demon-
strates that the model adequately fits the data chi-
square = 1.502, df = 6, p = .958. Table 5 gives coefficients and the
Wald statistic and associated degrees of freedom and probability
values for each of the predictor variables.
Similarly, to accepting a novel COVID-19 vaccination for them-
selves, participants that self-reported as Black, Asian, Chinese,
Mixed or Other ethnicity were 2.74 times (95%CI: 1.35–5.57) more
likely to reject a COVID-19 vaccine for their child than White Bri-
tish, White Irish and White Other participants. This finding was
also found for income, with participants in the lower household
income bracket (<£35,000) being 1.8 times (95%CI: 1.17–2.82) as
likely to reject a COVID-19 vaccine for their child than participants
with a medium household income (£35,000-£84,999). Participants
with more than four children were also found to be around four
times (OR 4.13; 95%CI: 1.873–9.104) more likely to reject the vac-
cination for their children than those with only one child, however,
caution should be taken with this finding due to the small sample
size.
5. Discussion
In this multi-methods study, the majority of parents and guar-
dians reported they would definitely accept or were unsure but
leaning towards accepting a COVID-19 vaccine for themselves
and their child/children.
Attitudes towards a COVID-19 vaccine appear more positive in
our study (in terms of the proportion of participants reporting they
would definitely accept or were leaning towards accepting vacci-
nation) than those reported in surveys conducted with adults in
France, Germany, Italy, Portugal, the Netherlands and the US
[11–13], and comparable to reports from Denmark and Australia
[12,14]. However, this could be due to differences in the questions
asked; highlighting the need for cross-country surveys and consis-
tency in the wording of questions. These surveys indicate that the
difference in vaccination acceptance ranges greatly between coun-
tries, from around 62% in France to 80% in Denmark and the UK
[12], and are reflective of trust in vaccines and health systems
more broadly, and in governments. More positive attitudes
towards COVID-19 vaccination in our study appear to reflect the
high level of parent trust in vaccines in the UK, and trust in the
NHS.
The main reasons, or ‘pros’ for vaccinating, were to protect the
individual being vaccinated against COVID-19, followed by pro-
tecting others from the disease. Uncertainties around vaccine
safety, effectiveness, and the benefit of vaccinating children were
the most prevalent reasons given for COVID-19 vaccine refusal.
Safety and effectiveness concerns were prompted by fears that
the accelerated vaccine development process, considered politi-
Table 4
Predictors of COVID-19 vaccine acceptance for self.
Univariable analysis Multivariable analysis
Variable Sig (p) OR 95% CI Sig (p) OR 95% CI
Age 0.008 – – 0.559 – –
18–23 0.017 3.575 1.257–10.165
24–30 0.004 1.860 1.216–2.844
31–36 y – – –
37–42 0.710 0.899 0.514–1.574
43+ 0.439 1.634 0.471–5.669
Household income <0.001 – – <0.001 – –
Low Income <£35,000 (n = 242) <0.001 2.535 1.677–3.832 0.002 2.087 1.317–3.307
Medium Income £35,000–£84,999 (n = 622)y – – – – – –
High Income >£85,000 (n = 260) <0.006 0.363 0.177–0.744 0.005 0.352 0.170–0.729
Employment <0.001 – – 0.033 – –
Working full-time (n = 628)y – – – – – –
Working part-time (n = 373) 0.802 0.943 0.596–1.491 0.229 0.739 0.452–1.209
Homemaker (n = 103) <0.001 3.025 1.784–5.130 0.038 1.888 1.035–3.445
Student (n = 10) 0.006 5.673 1.656 –19.436 0.311 2.076 0.506–8.524
Unemployed (n = 10) 0.009 5.042 1.504–16.903 0.224 2.474 0.575–10.651
Ethnicity 0.017 – – 0.010 – –
White (n = 1070)y – – – – – –
BAME (n = 54) 0.010 2.295 1.216–4.333 0.010 2.733 1.270–5.885
y Reference category.
Table 5
Predictors of COVID-19 vaccine acceptance for child
Univariable analysis Multivariable analysis
Variable Sig (p) OR 95% CI Sig (p) OR 95% CI
Employment <0.001 0.201
Working full-time (n = 628)y – – –
Working part-time (n = 373) 0.923 1.021 0.666–1.568
Homemaker (n = 103) <0.001 2.561 1.511–4.340
Student (n = 10) 0.074 3.377 0.891–12.805
Unemployed (n = 10) <0.001 8.684 2.829–26.660
Household income <0.001 0.001 – –
Low Income <£35,000 (n = 242) <0.001 2.291 1.521–3.451 0.007 1.826 1.178–2.830
Medium Income £35,000–£84,999 (n = 622)y – – – – – –
High Income >£85,000 (n = 260) 0.094 0.614 0.347–1.087 0.079 0.596 0.334–1.062
Number of children <0.001 0.004 – –
1 (n = 507)y – – – – – –
2 (n = 447) 0.289 1.249 0.828–1.882 0.409 1.206 0.773–1.880
3 (n = 133) 0.014 1.955 1.146–3.335 0.083 1.677 0.935–3.009
4 or more (n = 37) <0.001 4.250 2.044–8.836 <0.001 4.054 1.843–8.914
Ethnicity 0.038 0.009 – –
White (n = 1,070)y – – – – – –
BAME (n = 54) 0.027 2.046 1.087–3.852 0.009 2.549 1.259–5.159
yReference category.
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ous research also suggests that people consider older vaccines safer
than newer ones [15,16], and highlights the importance of trans-
parency in communicating about the vaccine development process
and of vaccination safety testing.
When a COVID-19 vaccine is launched, should any safety sig-
nals or safety concerns arise, it will be key for government and
public health officials to reassure the public with transparency,
action, accountability and timeliness in order to avoid any detri-
mental impact of the new vaccine on the current national immu-
nisation programme. The dengue vaccine controversy in the
Philippines highlights how safety concerns around a newly
launched vaccine, Dengvaxia, can derail a successful national
immunisation programme leading to drops in childhood vaccine
uptake, and even spill over to other health care treatments [17].
A number of safety scares have also derailed vaccine programmes7796in the past, including safety concerns around the HPV vaccine in
Japan which spread globally [18].
Other surveys have identified that views on COVID-19 vaccine
acceptance are influenced by vaccine efficacy and perceptions of
disease risk. In a cross-sectional survey conducted in Indonesia,
Harapan et al [19] found that 93.3% of participants would receive
a COVID-19 vaccine that was 95% effective but only 67.0% of partic-
ipants would accept a 50% effective vaccine. The authors also found
that acceptance was higher amongst participants that considered
themselves at greater risk of COVID-19 infection.
In our study, lower levels of vaccine acceptance for children
were discussed by parents in terms of children being at lower-
risk of COVID-19. Evidence suggests that children have lower sus-
ceptibility to COVID-19 [20], very few children develop severe
COVID-19 (even if they are in a clinical risk group), and their role
in the transmission of COVID-19 is unclear [21]. Similarly with
S. Bell, R. Clarke, S. Mounier-Jack et al. Vaccine 38 (2020) 7789–7798influenza vaccination, parents and guardians in our study more
often considered the perceived benefits to their child, rather than
societal benefits, as a reason to vaccinate their children [22].
5.1. Acting now to prevent inequalities in COVID-19 vaccine uptake
We found that participants of Black, Asian, Chinese, Mixed or
Other ethnicity were more likely to reject a COVID-19 vaccine for
themselves and their child/children compared to White partici-
pants (i.e. White British, White Irish or White Other). Comparably,
lower levels of COVID-19 vaccine acceptability in Black African and
lower income groups have been reported in US based surveys [13].
This is of concern given the evidence that Black, Asian and minority
ethnic (BAME) groups and people living in the most deprived areas
are at higher risk of acquiring COVID-19 infection and at increased
risk of death from COVID-19 [21]. Inequalities in vaccination
uptake amongst BAME communities [23–26] and lower income
groups [26,27] already exist for certain vaccines and a concerted
effort must be made to understand factors affecting vaccine accep-
tance and address potential ethnic inequalities in uptake of a
future COVID-19 vaccine. We were unable to explore further rea-
sons for ethnic differences in COVID-19 vaccine acceptance due
to insufficient representation of ethnic minority groups in writing
open-text responses and agreeing to participate in interviews.6. Strengths and limitations
The quality of the study was enhanced through the use of a
multi-methods approach in which interview and open-text
responses were used to develop insight into factors underpinning
quantitative responses. Our study took place at the height of the
COVID-19 pandemic in England and a survey repeated now that
we are ‘past the peak’ of COVID-19 cases and deaths and lockdown
has been eased may yield different responses. This has already
been indicated in the second wave of a large European survey look-
ing at COVID-19 vaccine attitudes [28]. This highlights the need for
longitudinal studies to measure the acceptability of a COVID-19
vaccine at different intervals.
Our recruitment strategy achieved a high number of responses
(n = 1252). Although largely representative geographically, our
sample lacked representability in terms of household income and
ethnicity. For example, in relation to ethnicity, according to the
2011 census 85% of the population in England was White. 94% of
our survey participants self-reported as White [29]. Our recording
of household income is not directly comparable to UK data from
the Office for National Statistics (ONS), as we did not specify if
the income value provided by survey participants should be pre
or post-tax and benefits, or take into account the number of house-
hold occupants. We also captured data for income in banded forms,
rather than asking for exact amounts. However, our sample
appears to have a much higher median household income
(£55,000-£64,999) than the median household income for the UK
(£29,600) [30]. This meant that although our sample size was large
enough to identify ethnicity and income as determinants of vac-
cine acceptance, it was not possible to explore differences in vacci-
nation views by these variables when looking at open-text
responses.7. Conclusion
The success of COVID-19 vaccination programmes will rely
heavily on public willingness to accept the vaccine. The main con-
cerns raised by parents in our study were around the safety and
effectiveness of a ‘rushed’ and new COVID-19 vaccine. To alleviate
these concerns, there needs to be clear communication and trans-7797parency as to how COVID-19 vaccines are developed and tested,
and safety and efficacy information.
Opening up a conversation with members of the public at an
early stage is key to understanding factors that may affect vaccine
acceptability, and developing approaches to allay any concerns.
This must happen in parallel with efforts to develop a COVID-19
vaccine.
Importantly, efforts must be made to understand and address
factors that may affect COVID-19 vaccine uptake in Black, Asian
and ethnic minority groups and lower-income households who
are disproportionately affected by COVID-19.
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